The National Institute of Mental Health’s STAR*D trial suggests that remission from a prototypical agent of the SSRI class occurs about one-third of the time with initial monotherapy in find more patients with MDD, and each subsequent ADT yields less favorable outcomes as treatment-resistant depression increases. After four successive ADTs,
about two-thirds of patients finally achieve remission, but many of these do not sustain remission for more than a few months [Rush et al. 2006]. Thus, one-third of patients with MDD continue to have significant symptoms after treatment with a sequence of agents for about Inhibitors,research,lifescience,medical a year, and many of those who achieve remission do not sustain it. Given these modest results, researchers continue to look for new ways to treat depression and with novel pharmacologic mechanisms. In the absence of a remarkable breakthrough drug in the area of nonmonoamine agents, that is, hormonal,
Inhibitors,research,lifescience,medical peptide, genetic, neuromodulation [Schwartz, 2010], clinicians have resorted to higher levels of rational polypharmacy Inhibitors,research,lifescience,medical in order to gain full remission when monotherapies fail by using combination drug treatment earlier and earlier in treatment selection [Blier et al. 2010; Rush, 2010; Schwartz and Rush, 2007]. To boost antidepressant efficacy in patients whose condition fails to respond adequately to an SSRI, numerous second-generation Inhibitors,research,lifescience,medical atypical antipsychotics (SGAs) are now approved: aripiprazole, quetiapine, quetiapine XR, olanzapine—fluoxetine combination, but with potential additional side effects and costs [Weisler et al. 2009; Corya Inhibitors,research,lifescience,medical et al. 2006]. A unique mechanistic approach is that of vilazodone, an agent that combines two mechanisms
in a single drug, namely that of the SSRIs with 5HT1A receptor partial agonist actions, or a serotonin partial agonist reuptake inhibitor (SPARI). Specifically, this agent increases the availability and activity of the neurotransmitter serotonin Edoxaban and its neuropathways. Vilazodone blocks the serotonin reuptake pump (serotonin transporter or SERT), desensitizes serotonin receptors (especially 5HT1A autoreceptors), and therefore presumably increases serotonergic neurotransmission. Its partial agonist actions at presynaptic somatodendritic 5HT1A autoreceptors may theoretically enhance serotonergic activity and contribute to antidepressant actions as well [Stahl, 2011; Hudziak, 2005; Pies, 1998]. This partial agonist action also occurs at the level of the postsynaptic 5HT1A receptor, which may theoretically diminish sexual dysfunction [Hudziak, 2005; Pies, 1998].